Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

EKSO vs PLSE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PLSE Captures Overall Composite Edge (64.2 BUY vs 58.1 HOLD), While EKSO Leads 3–2 on Growth & Valuation Pillars

PLSE Overall Winner 6-Pillar Tally: EKSO 3 – 2 PLSE (1 Tie) Matrix Metrics: EKSO 2 – 5 PLSE

As of Nov 20, 2026, Pulse Biosciences, Inc (PLSE) captures the overall head-to-head institutional edge over Ekso Bionics Holdings, Inc. (EKSO) on higher Unified Composite conviction (64.2/100 BUY vs. 58.1/100 HOLD) after splitting the core matrix 5–2 (led by Growth & Scale, Options & Positioning), while EKSO wins 3–2 across the 6-pillar growth and valuation breakdown. EKSO trades at $11.80 (N/M Forward P/E, -119.7% operating margin) versus PLSE at $45.55 (N/M Forward P/E, -5861.2% operating margin).

  • Growth vs. Quality Trade-Off: PLSE earns the overall head-to-head edge with a stronger Unified Composite Score (64.2/100 BUY vs. EKSO 58.1/100 HOLD) and 1.71β · 76% Vol risk profile, whereas EKSO leads top-line expansion (-38.3% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EKSO vs PLSE
EKSO NASDAQ
Ekso Bionics Holdings, Inc. Common Stock
General Industrial Machinery & Equipment, Nec
$11.80
+0.08% 1D
Market Cap $42.0M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 2.16β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 60
RSI-14: 60.4 · SMA20: $10.56 · SMA50: $10.65
PLSE NASDAQ Head-to-Head Winner
Pulse Biosciences, Inc Common Stock (DE)
Surgical & Medical Instruments & Apparatus
$45.55
+2.57% 1D
Market Cap $3.3B
TTM Revenue $1.5M
Forward P/E N/M
Beta / 30D Vol 1.71β · 76% Vol
Unified Composite Score
64.2 / 100 BUY
Tech 63.0 Fund 60.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 40.9 · SMA20: $51.79 · SMA50: $51.15

6-Pillar Scorecard Institutional Category Breakdown (EKSO 3 – 2 PLSE)

Columns: Metric · EKSO · PLSE
1. Valuation Multiples EKSO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.3x N/M
2. Growth & Scale PLSE
Revenue Growth (YoY) -38.3% +359.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $13M $1.5M
Market Cap $42.0M $3.3B
3. Profitability & Quality EKSO
Gross Margin 53.5% 26.8%
Operating Margin -119.7% -5861.2%
Net Profit Margin -91.4% 0.0%
Return on Equity (ROE) -107.6% -60.6%
4. Balance Sheet & Cash Flow EKSO
Cash Generation (TTM) -$11M EBITDA -$64M
Cash Flow Margin -86.0% EBITDA Mgn N/A
Net Cash / Leverage $2.54 Book/Sh · -107.6% ROE $30M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PLSE
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 77.6% (10th %ile)
Put/Call OI Skew N/A 43.67x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EKSO (2) vs PLSE (5)
Institutional Metric EKSO PLSE Criterion Row Edge
Market Capitalization
Scale
$42.0M $3.3B Larger Scale PLSE
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-38.3% +359.3% Higher Growth PLSE
Operating Margin (TTM)
Profitability
-119.7% -5861.2% Higher Margin EKSO
Net Profit Margin
Profitability
-91.4% 0.0% Higher Margin PLSE
Return on Equity (ROE)
Capital Efficiency
-107.6% -60.6% Higher ROE PLSE
52-Week Range Position
Momentum
87% ($0–$14) 71% ($13–$59) Stronger Trend EKSO
Beta / 30D Volatility
Risk Regime
2.16β · 76% Vol 1.71β · 76% Vol Lower Realized Risk Tie
Unified Institutional Score
Composite Signal
58.1 / 100 (HOLD) 64.2 / 100 (BUY) Higher Composite PLSE
Trailing 12M Revenue (USD)
Operating Scale
$13M $1.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
53.5% 26.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($2.54 Book/Sh · -107.6% ROE) -$64M ($30M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EKSO +38.44 pp
EKSO: +25.53% · PLSE: -12.91%
3M Horizon PLSE +20.17 pp
EKSO: +25.93% · PLSE: +46.1%
6M Horizon EKSO +138.84 pp
EKSO: +192.8% · PLSE: +53.96%
1Y Horizon EKSO +138.84 pp
EKSO: +192.8% · PLSE: +53.96%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EKSO vs PLSE. Trailing 12-month operating profitability (EKSO -119.7% vs PLSE -5861.2%) and valuation multiples (EKSO N/M vs PLSE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EKSO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross Margin53.5%
Op. Margin-119.7%
ROE / Fwd P/E-107.6% · N/M
PLSE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.5M
Gross Margin26.8%
Op. Margin-5861.2%
ROE / Fwd P/E-60.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EKSO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EKSO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PLSE CONSOLIDATION
55d in phase · OBV DISTRIBUTION
Current IV 77.6%
IV Percentile 10th %ile
Put/Call OI Skew 43.67x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact PLSE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EKSO Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $42.0M market capitalization and -119.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PLSE Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $3.3B market capitalization and -5861.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EKSO vs PLSE Key Questions & Quantitative Answers

As of Nov 20, 2026, Pulse Biosciences, Inc (PLSE) captures the overall head-to-head institutional edge over Ekso Bionics Holdings, Inc. (EKSO) on higher Unified Composite conviction (64.2/100 BUY vs. 58.1/100 HOLD) after splitting the core matrix 5–2 (led by Growth & Scale, Options & Positioning), while EKSO wins 3–2 across the 6-pillar growth and valuation breakdown. EKSO trades at $11.80 (N/M Forward P/E, -119.7% operating margin) versus PLSE at $45.55 (N/M Forward P/E, -5861.2% operating margin). Growth vs. Quality Trade-Off: PLSE earns the overall head-to-head edge with a stronger Unified Composite Score (64.2/100 BUY vs. EKSO 58.1/100 HOLD) and 1.71β · 76% Vol risk profile, whereas EKSO leads top-line expansion (-38.3% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

PLSE leads the Growth & Scale pillar: EKSO posts -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin), compared with PLSE at +359.3% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (26.8% gross margin, -5861.2% operating margin). On trailing 12-month operating scale, EKSO generates $13M in USD-normalized revenue versus $1.5M for PLSE. In operating R&D and SG&A reinvestment, EKSO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PLSE.

EKSO screens cheaper on headline valuation multiples. EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin), whereas PLSE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EKSO (-107.6% ROE) versus PLSE (-60.6% ROE) capital efficiency.

In options market volatility and institutional positioning, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk). By comparison, PLSE carries 77.6% implied volatility (10th %ile, Compressed (<25th %ile)), a 43.67x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.71β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.